title: CBFA2, frequently rearranged in leukemia, is not responsible for a familial leukemia syndrome.
abstract: We have identified a family with an autosomal dominant platelet disorder with a predisposition for developing myeloid malignancies and have previously demonstrated linkage of this trait to chromosome 21q22.1-22.2. The nearest flanking markers, D21S1265 and D21S167, define the familial platelet disorder (FPD) critical region at a genetic distance of approximately 15.2 centimorgans and physical distance of approximately 6 megabases. This locus is of particular interest as it has previously been implicated in the pathogenesis of acute myelogenous leukemia (AML) and acute lymphoblastic leukemia (ALL) through the (8;21), (3;21) and (12;21) chromosomal translocations. In each of these cases, the CBFA2 gene is rearranged. As well, there is a potential association of this locus with the hematologic abnormalities seen in Down syndrome (trisomy 21). To identify the mutant gene in this pedigree, a positional cloning strategy has been undertaken. Several candidate genes map to this locus including: CBFA2, IFNAR1, IFNAR2, CRFB4, GART, SON, KCNE1, SCL5A3 and ATP50. CBFA2, as well as IFNAR1 and CRFB4, were the focus of initial mutational analysis efforts. In this report, we exclude CBFA2 as a candidate by Northern and Southern blotting, RNase protection, single-strand conformational polymorphism (SSCP), direct sequencing and gel-shift analysis. Exons of the IFNAR1 and CRFB4 genes were also analyzed by SSCP and demonstrated no evidence of mutation. SSCP analysis identified a new polymorphism in the second exon of the CRFB4 gene and confirmed a previously described polymorphism in the fourth exon of IFNAR1. Efforts are currently underway to delimit further the FPD critical region and to analyze the other known candidate genes, as well as novel candidate genes, which map to this locus.
authors.affiliation: Department of Medicine, Harvard Medical School, Boston, MA, USA.
authors.forename: R D
authors.initials: RD
authors.lastname: Legare
authors.forename: D
authors.initials: D
authors.lastname: Lu
authors.forename: M
authors.initials: M
authors.lastname: Gallagher
authors.forename: C
authors.initials: C
authors.lastname: Ho
authors.forename: X
authors.initials: X
authors.lastname: Tan
authors.forename: G
authors.initials: G
authors.lastname: Barker
authors.forename: K
authors.initials: K
authors.lastname: Shimizu
authors.forename: M
authors.initials: M
authors.lastname: Ohki
authors.forename: N
authors.initials: N
authors.lastname: Lenny
authors.forename: S
authors.initials: S
authors.lastname: Hiebert
authors.forename: D G
authors.initials: DG
authors.lastname: Gilliland
mesh_terms: D050676:Core Binding Factor Alpha 2 Subunit; D018076:DNA, Complementary / Q000737:chemistry; D004268:DNA-Binding Proteins; D005091:Exons; D015321:Gene Rearrangement; D006801:Humans; D007938:Leukemia / Q000235:genetics*; D009154:Mutation; D018807:Polymorphism, Single-Stranded Conformational; D011518:Proto-Oncogene Proteins; D014157:Transcription Factors / Q000235:genetics*
chemical_list: D050676:Core Binding Factor Alpha 2 Subunit; D018076:DNA, Complementary; D004268:DNA-Binding Proteins; D011518:Proto-Oncogene Proteins; C493728:RUNX1 protein, human; D014157:Transcription Factors